Qualigen Therapeutics, Inc. (NASDAQ:QLGN) has a beta value of -0.65 and has seen 359,481 shares traded in the last trading session. The company, currently valued at $81.64 Million, closed the last trade at $3.54 per share which meant it lost -$0.1 on the day or -2.75% during that session. The QLGN stock price is -507.35% off its 52-week high price of $21.5 and 10.17% above the 52-week low of $3.18. If we look at the company’s 10-day average daily trading volume, we find that it stood at 657.66 Million shares traded. The 3-month trading volume is 821.67 Million shares.
The consensus among analysts is that Qualigen Therapeutics, Inc. (QLGN) is a Buy stock at the moment, with a recommendation rating of 2. None of the analysts rate the stock as a Sell, while none rate it as Overweight. None out of 1 have rated it as a Hold, with 1 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is $0.03.
Qualigen Therapeutics, Inc. (NASDAQ:QLGN) trade information
Despite being -2.75% in the red today, the stock has traded in the green over the last five days, with the highest price hit on Wednesday, Nov 18 when the QLGN stock price touched $3.84-7 or saw a rise of 7.81%. Year-to-date, Qualigen Therapeutics, Inc. shares have moved -16.16%, while the 5-day performance has seen it change 2.91%. Over the past 30 days, the shares of Qualigen Therapeutics, Inc. (NASDAQ:QLGN) have changed -20.45%. Short interest in the company has seen 1.52 Million shares shorted with days to cover at 0.
Wall Street analysts have a consensus price target for the stock at $10, which means that the shares’ value could jump 182.49% from current levels. The projected low price target is $10 while the price target rests at a high of $10. In that case, then, we find that the current price level is +182.49% off the targeted high while a plunge would see the stock lose 182.49% from current levels.
Qualigen Therapeutics, Inc. (QLGN) estimates and forecasts
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was +28% over the past 5 years. Earnings growth for 2020 is a modest +71.1%.
Qualigen Therapeutics, Inc. (NASDAQ:QLGN)’s Major holders
Insiders own 12.51% of the company shares, while shares held by institutions stand at 3.75% with a share float percentage of 4.28%. Investors are also buoyed by the number of investors in a company, with Qualigen Therapeutics, Inc. having a total of 24 institutions that hold shares in the company. The top two institutional holders are Blackrock Inc. with over 314.13 Thousand shares worth more than $1.55 Million. As of September 29, 2020, Blackrock Inc. held 1.36% of shares outstanding.
The other major institutional holder is Vanguard Group, Inc. (The), with the holding of over 305.95 Thousand shares as of September 29, 2020. The firm’s total holdings are worth over $1.51 Million and represent 1.33% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Fidelity NASDAQ Composite Index Fund and Vanguard Extended Market Index Fund. As of August 30, 2020, the former fund manager holds about 0.05% shares in the company for having 10616 shares of worth $51.06 Thousand while later fund manager owns 3.64 Thousand shares of worth $14.46 Thousand as of June 29, 2020, which makes it owner of about 0.02% of company’s outstanding stock.